François Bocquet(1)(2)(3), Pascal Paubel (1)(2)(3) (1)Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cite, Paris, France (2)Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cite, Paris, France (3)General Agency of Equipment and Health Products (AGEPS), Assistance Publique-H^opitaux de Paris (AP-HP), Paris, France The global biologics market—which is forecast to be worth […]
François Bocquet (1) (2) (3), Pascal Paubel (2), Isabelle Fusier (3), Anne-Laure Cordonnier (3), Claude Le Pen (1), Martine Sinègre (3). (1) Dauphine University, Paris, France, (2) Paris Descartes University, France, (3) General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-‐HP), France Objectives Analyze factors influencing Erythropoietins (EPO) biosimilars (copies of […]
François Bocquet (1) (2) (3), Pascal Paubel (3), Isabelle Fusier, Anne-Laure Cordonnier, Claude Le Pen (2), Martine Sinègre. Appl Health Econ Health Policy, 2014; 12 (3) : 315-326. (1) Therapeutic Evaluation Unit, General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France (2) Dauphine University, Paris, France (3) Faculty of […]
Bocquet F (1), (2), (3), Paubel P (2), Fusier I (3), Cordonnier AL (3), Le Pen C (1), Sinègre N (3) (1) Dauphine University, Paris, France, (2) Paris Descartes University, France, (3) General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), France Objectives: To determine the ability of biosimilars (copies of […]
